CAMBRIDGE, Mass. — SpyBiotech, a biotechnology company developing next-generation vaccine platform technologies, has appointed Stuart Chaffee, Ph.D., as an independent member of its Board of Directors.
Currently the CEO of QuantX Biosciences, Chaffee brings more than 20 years of leadership experience in the biotech and biopharma sectors. He has been a key figure in the founding of four publicly traded biotech companies and has played a leading role in securing over $900 million in combined private and public funding. Most notably, as Chief Business Officer at Affinivax, Inc., he helped drive the company’s strategic expansion, ultimately leading to its acquisition by GSK for up to $3.3 billion.
Chaffee’s extensive background in business development and corporate strategy is expected to help guide SpyBiotech as it continues to advance its proprietary SpyTag/SpyCatcher™ protein “superglue” platform and bring new vaccine candidates into the clinic.
SpyBiotech’s platform is built around its SpyTag/SpyCatcher technology, which allows for the rapid and stable binding of antigens to vaccine delivery systems. The platform is designed to enhance immunogenicity and reduce development risks through a modular, plug-and-play approach. The company recently completed vaccinations in a Phase I trial for SPYVLP01, its cytomegalovirus (CMV) vaccine candidate—marking a major milestone in efforts to combat a virus associated with long-term developmental disorders.
“I am honored to join SpyBiotech’s Board at such an exciting juncture in the company’s journey,” said Chaffee. “SpyBiotech’s innovative SpyTag/SpyCatcher platform and focus on transformative vaccine development resonate deeply with my commitment to patient-centered innovation. I look forward to helping accelerate the company’s growth and impact.”
Eddie Gray, Chairman of SpyBiotech, welcomed Chaffee’s appointment, stating, “Stuart’s proven ability to build and scale high-value biotech ventures, along with his deep strategic insight, make him an invaluable addition to our Board. His guidance will be instrumental as we advance our clinical programs and leverage our platform to address urgent global health threats.”
The appointment underscores SpyBiotech’s momentum as it continues to expand its pipeline and prepare for future clinical milestones.
